<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736485</url>
  </required_header>
  <id_info>
    <org_study_id>2020-004497-21</org_study_id>
    <nct_id>NCT04736485</nct_id>
  </id_info>
  <brief_title>Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)</brief_title>
  <acronym>GASPAR</acronym>
  <official_title>Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or&#xD;
      gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001)&#xD;
      in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response after pre-operative treatment</measure>
    <time_frame>At surgery, an average 3 months after treatment initiation</time_frame>
    <description>Proportion of patients with pCR (pathologic complete response) in the primary tumour defined as: no tumour residue found in the tissue collected during the surgery evaluated by the pathologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of perioperative treatment on disease-free survival</measure>
    <time_frame>Through study completion, an average of 5 follow-up year</time_frame>
    <description>Disease-free survival (DFS) defined as time between inclusion and first disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of perioperative treatment on overall survival</measure>
    <time_frame>Up to death</time_frame>
    <description>Overall survival (OS) defined as the time between inclusion and death whatever cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The correlation between pathologic Complete response and survival outcomes (disease-free and overall survival)</measure>
    <time_frame>At surgery, an average 3 months after treatment initiation</time_frame>
    <description>Proportion of patients with margin-free resection (R0), defined as a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events</measure>
    <time_frame>Toxicities occurring up to 1 month after the end of treatment</time_frame>
    <description>Type, grade and number of Adverse Events as Assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Gastric Cancer by AJCC V8 Stage</condition>
  <condition>Resectable Carcinoma</condition>
  <arm_group>
    <arm_group_label>FLOT regimen plus Spartalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard FLOT regimen&#xD;
Docetaxel 50 mg/m² IV infusion on D1&#xD;
Oxaliplatine 85 mg/m² IV infusion on D1&#xD;
Leucovorin 200 mg/m² IV infusion on D1&#xD;
Fluorouracile 2600 mg/m² 24 h IV infusion on D1&#xD;
with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perioperative treatment</intervention_name>
    <description>FLOT + Spartalizumab</description>
    <arm_group_label>FLOT regimen plus Spartalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Untreated localized gastric or GEJ adenocarcinoma considered resectable (clinical&#xD;
             stage ≥cT2 and/or cN+ and no metastasis)&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1&#xD;
&#xD;
          -  Tumor tissue must be provided for biomarker analyses (fresh or archival with an FFPE&#xD;
             tissue block)&#xD;
&#xD;
          -  All subjects must consent to allow the acquisition of blood samples for performance of&#xD;
             correlative studies&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria:&#xD;
&#xD;
               -  WBC ≥ 2000/ mm³&#xD;
&#xD;
               -  Neutrophils ≥ 1500/ mm³&#xD;
&#xD;
               -  Platelets ≥ 100 000/ mm³&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 3 x ULN&#xD;
&#xD;
               -  Measured or calculated creatinine ≥ 50 ml/min clearance (CrCl) (using the&#xD;
                  Cockcroft-Gault formula)&#xD;
&#xD;
               -  Potassium ≥ LLN&#xD;
&#xD;
               -  Magnesium ≥ LLN&#xD;
&#xD;
               -  Calcium ≥ LLN&#xD;
&#xD;
          -  Female subject of childbearing potential must have a negative urine or serum pregnancy&#xD;
             test within 72h before study start&#xD;
&#xD;
          -  Subject in reproductive age must be willing to use adequate contraception during the&#xD;
             study and at least 9 months in men and 12 months in women after the last dose of&#xD;
             investigational drug. In addition, given the toxicities observed on the male&#xD;
             reproductive system, a conservation of gametes will be proposed for men, as usually in&#xD;
             routine practice&#xD;
&#xD;
          -  Subject affiliated to a social security regimen&#xD;
&#xD;
          -  Patient has signed informed consents obtained before any trial related activities and&#xD;
             according to local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subject with any distant metastasis&#xD;
&#xD;
          -  Subject with no recovering from the effects of major surgery or significant traumatic&#xD;
             injury within 14 days before inclusion&#xD;
&#xD;
          -  Documented significant cardiovascular disease within the past 6 months before the&#xD;
             first dose of study treatment, including: history of congestive heart failure (defined&#xD;
             as NYHA III or IV), myocardial infarction, unstable angina, coronary angioplasty,&#xD;
             coronary stenting, coronary artery bypass graft, cerebrovascular accident or&#xD;
             hypertensive crisis&#xD;
&#xD;
          -  History of anterior organ transplant, including stem cell allograft&#xD;
&#xD;
          -  Pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  History of other malignancy within the previous 3 years (except for appropriately&#xD;
             treated in-situ cervix carcinoma and non-melanoma skin carcinoma)&#xD;
&#xD;
          -  Subject with active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Subject with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of start of study treatment GASPAR Protocol - EUDRACT number: 2020-004497-21 -&#xD;
             version 1.3 / 2021-01-18 Page 8 sur 44&#xD;
&#xD;
          -  Known history of HIV or HBV infection&#xD;
&#xD;
          -  Known active HCV infection&#xD;
&#xD;
          -  Known history of active tuberculosis&#xD;
&#xD;
          -  Vaccination with live vaccine within 30 days before the first dose of study treatment&#xD;
&#xD;
          -  Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or&#xD;
             drug specifically targeting T-cell co-stimulation or checkpoint pathways&#xD;
&#xD;
          -  Recent or concomitant treatment with brivudine (herpes virostatic)&#xD;
&#xD;
          -  Prior anticancer therapy for the current malignancy&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs or their excipients&#xD;
&#xD;
          -  Chronic inflammable gastro-intestinal disease&#xD;
&#xD;
          -  Uracilemia ≥ 16 ng/ml&#xD;
&#xD;
          -  QT/QTc &gt; 450 msec for men and &gt; 470 msec for women&#xD;
&#xD;
          -  Peripheral neuropathy ≥ Grade II&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Participation in another therapeutic clinical study&#xD;
&#xD;
          -  Patient deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
          -  Patient assessed by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mélanie DOS SANTOS, MD</last_name>
    <phone>33231455050</phone>
    <email>m.dossantos@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mélanie DOS SANTOS, MD</last_name>
      <email>m.dossantos@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>perioperative</keyword>
  <keyword>spartalizumab</keyword>
  <keyword>PDR001</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

